Status:

COMPLETED

A Clinical Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033)

Lead Sponsor:

Merck Sharp & Dohme LLC

Conditions:

Healthy

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

The goal of the study is to learn what happens to enlicitide decanoate in a healthy person's body over time when taken on an empty stomach or with food. Researchers will compare what happens to enlici...

Eligibility Criteria

Inclusion

  • The main inclusion criteria include but are not limited to the following:
  • \- Has body mass index (BMI) ≥18 kg/m\^2 and ≤32 kg/m\^2

Exclusion

  • The main exclusion criteria include but are not limited to the following:
  • History of gastrointestinal disease which may affect food and drug absorption, or has had a gastric bypass or similar surgery
  • History of cancer (malignancy)
  • Positive test(s) for Hepatitis B surface antigen (HBsAg), hepatitis C antibodies or Human immunodeficiency virus (HIV)
  • History of a major surgery
  • Is lactose intolerant

Key Trial Info

Start Date :

October 21 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 31 2025

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT06609512

Start Date

October 21 2024

End Date

January 31 2025

Last Update

February 7 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Celerion ( Site 0001)

Tempe, Arizona, United States, 85283